Tesamorelin Therapy
What is Tesamorelin?
Tesamorelin (brand name Egrifta) is a growth hormone-releasing hormone (GHRH) analog FDA-approved for reducing excess abdominal fat in HIV-positive patients with lipodystrophy. It stimulates the pituitary gland to produce natural growth hormone, which in turn promotes fat metabolism. It is increasingly used off-label for general visceral fat reduction and anti-aging purposes.
Benefits & Uses
Targeted reduction of visceral abdominal fat, improved body composition, stimulates natural GH production rather than providing synthetic GH, may improve cognitive function and reduce liver fat.
Potential Side Effects
Injection site reactions, joint pain, muscle pain, peripheral edema, hyperglycemia. Not recommended during pregnancy. May worsen pre-existing malignancies.
Find Tesamorelin Providers Near You
Browse 17 providers offering Tesamorelin therapy in our directory.
Browse ProvidersFrequently Asked Questions
Targeted reduction of visceral abdominal fat, improved body composition, stimulates natural GH production rather than providing synthetic GH, may improve cognitive function and reduce liver fat.
Tesamorelin therapy typically costs between $300 and $600 per month, though prices vary by provider, location, and dosage.
Tesamorelin has an FDA status of "FDA-approved". It has been approved by the FDA for specific indications. Your provider can explain the approved uses and any off-label applications.
Injection site reactions, joint pain, muscle pain, peripheral edema, hyperglycemia. Not recommended during pregnancy. May worsen pre-existing malignancies.
PeptideProbe lists 17 providers offering Tesamorelin therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.
Related Peptides
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.